Intellectual Property

NeoImmuneTech obtained the right on development and commercialization of Hyleukin as well as other undisclosed hyFc-based products from Genexine, Inc. (www.genexine.com) for the territory including North America, South America, and Europe.

Title Country Patent Application No. Original Assignee Filing Date
Immunoglobulin Fusion Proteins US 7867491 Genexine, Inc. /POSTECH 2010.12.28
Chimeric Immunoglobulin Fusion Proteins US 8586038 Genexine, Inc. 2013.11.19
Immunoglobulin Fusion Proteins EP 2162472 Genexine, Inc. /POSTECH 2010.03.17
Immunoglobulin Fusion Proteins CA 2687377 Genexine, Inc. /POSTECH 2013.05.14
Novel Immunotherapy KR 2015-0043564 Genexine, Inc. /BioDion Co.,Ltd 2015
Modified interleukin-7 protein and uses thereof KR 2015-0082793 Genexine, Inc. 2015
To install the latest Internet Explorer